Tagrisso (osimertinib) / AstraZeneca  >>  Phase 3
Welcome,         Profile    Billing    Logout  

41 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tagrisso (osimertinib) / AstraZeneca
AURA3, NCT02151981 / 2014-000594-39: AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark AURA3 trial in 2L T790M NSCLC at WCLC 2016
Dec 2016 - Dec 2016: AURA3 trial in 2L T790M NSCLC at WCLC 2016
Checkmark AURA-3 trial in NSCLC
Jul 2016 - Jul 2016: AURA-3 trial in NSCLC
Checkmark Initiation of P3 AURA3 trial for TKI failure and primary resistance mutation T790M advanced EGFRm+ NSCLC
More
Active, not recruiting
3
419
Europe, Canada, Japan, US, RoW
Chemotherapy, Osimertinib, Platinum-based Doublet-Chemotherapy, Cross-over to Osimertinib
AstraZeneca
Anticancer Treatment
04/16
12/23
FLAURA, NCT02296125 / 2014-002694-11: AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Checkmark Data from FLAURA study for NSCLC
Mar 2021 - Mar 2021: Data from FLAURA study for NSCLC
Checkmark From FLAURA trial for 1st-line EGFR + NSCLC
Oct 2018 - Oct 2018: From FLAURA trial for 1st-line EGFR + NSCLC
Checkmark In 1L EGFR mutated NSCLC
More
Active, not recruiting
3
674
Europe, Canada, Japan, US, RoW
AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Tarceva 150/100 mg, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Erlotinib 150/100 mg, Tarceva 150/100 mg, Gefitinib 250 mg, Iressa 250mg, Placebo AZD9291 80 mg/ 40 mg
AstraZeneca, Parexel
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
06/17
01/25
CAURAL, NCT02454933: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Checkmark CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Feb 2019 - Feb 2019: CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Checkmark Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Apr 2016 - Apr 2016: Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Completed
3
29
Canada, RoW
AZD9291, MEDI4736
AstraZeneca
Locally Advanced or Metastatic EGFR T790M+ NSCLC
08/17
06/23
NCT02959749: Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Completed
3
147
RoW
Osimertinib, docetaxel, bevacizumab
Qingdao Central Hospital
Progression Free Survival
10/17
12/17
ADELOS, NCT02997501: T790M Plasma Testing Methodology Comparison and Clinical Validation

Completed
3
256
RoW
T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG, Visual Slit-Lamp Testing, AZD9291 Dosing, Plasma AZD9291 testing
AstraZeneca, TigerMed
Lung Cancer
10/18
10/18
RELAY, NCT02411448 / 2014-004824-22: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC

Checkmark Presentation of data from RELAY trial in combination with erlotinib in 1L treatment of NSCLC at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from RELAY trial in combination with erlotinib in 1L treatment of NSCLC at ESMO 2020
Checkmark From RELAY trial in combination with erlotinib for 1L EGFR-mutated NSCLC
Oct 2019 - Oct 2019: From RELAY trial in combination with erlotinib for 1L EGFR-mutated NSCLC
Checkmark From RELAY trial in combination with Tarceva for 1L EGFR NSCLC at ASCO 2019
More
Active, not recruiting
3
545
Europe, Canada, Japan, US, RoW
Ramucirumab, LY3009806, Placebo, Erlotinib, Gefitinib, Osimertinib
Eli Lilly and Company
Metastatic Non-Small Cell Lung Cancer
01/19
12/24
ASTRIS, NCT02474355 / 2015-001407-31: Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Completed
3
3017
Europe, Canada, RoW
T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG, Visual Slit-Lamp Testing, AZD9291 Dosing
AstraZeneca, Parexel
Lung Cancer
04/19
04/19
APOLLO, NCT02972333: Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Unknown status
3
150
NA
AZD9291 80mg oral each day, AZD9291, 80mg, QD, p.o. (2nd line or later), Radiation therapy, WBRT or SRS
Shandong Cancer Hospital and Institute, AstraZeneca
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
09/19
12/19
ADAURA, NCT02511106 / 2015-000662-65: AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Checkmark DFS of five and a half years from ADAURA trial for adjuvant treatment of EGFRm NSCLC
Sep 2022 - Sep 2022: DFS of five and a half years from ADAURA trial for adjuvant treatment of EGFRm NSCLC
Checkmark Exploratory and post-hoc analysis data from ADAURA study
Jan 2021 - Jan 2021: Exploratory and post-hoc analysis data from ADAURA study
Checkmark From ADAURA trial in adjuvant EGFRm NSCLC at ESMO 2020
More
Active, not recruiting
3
682
Europe, Canada, Japan, US, RoW
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
AstraZeneca
Stage IB-IIIA Non-small Cell Lung Carcinoma
04/22
01/29
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Not yet recruiting
3
204
Europe
Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04]
 
 
2021-001825-33: A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Not yet recruiting
3
690
Europe, RoW
Amivantamab, Lazertinib, JNJ-61186372, JNJ-73841937/YH-25448, Solution for infusion, Tablet
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research and Development, Janssen Cilag SpA
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, A specific type of lung cancer called "Non-Small Cell Lung Cancer", Diseases [C] - Cancer [C04]
 
 
2021-004135-89: A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small cell lung cancer, following complete tumour resection. Ensayo clínico para investigar la eficacia y seguridad de Osimertinib versus Placebo en pacientes en estadío IA2-IA3 de cáncer de pulmón no microcítico, tras la resección completa del tumor.

Not yet recruiting
3
380
Europe
Osimertinib 40 mg, Osimertinib 80 mg, AZD9291, Film-coated tablet, Tagrisso
AstraZeneca AB, ASTRAZENECA AB, AstraZenecaAB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. Estadio IA2-IA3 de cáncer de pulmón no microcítico, positivo para la mutación de EGFR (Ex19del, L858R), tras la resección completa del tumor., Specific type of lung cancer called non-small cell lung cancer (NSCLC) stage IA2-IA3 with EGFR mutations positive after complete surgical removal of a tumour between 1 and 3 centimetres. Tipo específico de cáncer de pulmón no microcítico (CPNM) en estadío IA2-IA3 positivo para mutaciones de EGFR, tras la resección completa del tumor entre 1 y 3 centímetros., Diseases [C] - Cancer [C04]
 
 
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico

Not yet recruiting
3
324
Europe
Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2022-000525-25: A Clinical Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy Uno studio clinico di lazertinib con amivantamab per via sottocutanea somministrato tramite iniezione manuale rispetto ad amivantamab per via endovenosa o ad amivantamab per via sottocutanea in pazienti con carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR dopo progressione durante il trattamento con osimertinib e chemioterapia

Ongoing
3
640
Europe
Amivantamab (JNJ-61186372), Amivantamab (JNJ-61186372) co-formulated with recombinant human hyaluronidase (rHuPH20), Amivantamab JNJ-61186372 co-formulated with recombinant human hyaluronidase (rHuPH20) OBDS, Lazertinib mesylate monohydrate, [JNJ-61186372], [JNJ-73841937-ZCY/YH25448AM], Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Film-coated tablet
JANSSEN CILAG INTERNATIONAL NV, Janssen-Cilag International NV, Janssen Research & Development, LLC
EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR, A specific type of lung cancer called "Non-Small Cell Lung Cancer" carcinoma polmonare non a piccole cellule, Diseases [C] - Cancer [C04]
 
 
TOP, NCT04695925: Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations

Not yet recruiting
3
291
RoW
Osimertinib 80 MG [Tagrisso], Pemetrexed 500 MG Injection, Carboplatin
Li Zhang, MD
Non-small Cell Carcinoma, EGFR Gene Mutation
09/22
12/23
GEOMETRY-E, NCT04816214 / 2020-003677-21: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Terminated
3
6
Japan, RoW
Capmatinib, INC280, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
12/22
12/22
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - PDUFA date for FDA approval in adults with locally advanced/metastatic EGFRm NSCLC (based on FLAURA2 trial)
Jan 2022 - Dec 2023: Data from FLAURA2 trial in combination with carboplatin or pemetrexed/cisplatin for 1L EGFRm NSCLC
Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
AstraZeneca
Non-Small Cell Lung Cancer
04/23
06/26
MARIPOSA-2, NCT04988295: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting
3
776
Europe, Canada, Japan, US, RoW
Lazertinib, JNJ-73841937, YH-25448, Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
07/23
12/25
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
PALOMA-3, NCT05388669 / 2022-000525-25: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Active, not recruiting
3
418
Europe, Canada, Japan, US, RoW
Lazertinib, JNJ-73841937, YH25448, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), JNJ-61186372, Amivantamab Intravenous
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Advanced or Metastatic Non-small Cell Lung Cancer
01/24
01/25
NCT05104281: Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Recruiting
3
60
RoW
osimertinib oral and bevazizumab intravenously, bevacizumab, osimertinib
Qingdao Central Hospital
Carcinoma, Non-Small-Cell Lung
12/23
12/24
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
NCT06323148: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Not yet recruiting
3
226
NA
Osimertinib, No adjuvant therapy
Fudan University
Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease
03/26
03/29
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting
3
398
NA
JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
03/27
03/28
TROPION-Lung14, NCT06350097: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
582
Europe, RoW
Osimertinib, Osimertinib: AZD9291, Datopotamab Deruxtecan: Dato-DXd, Datopotamab Deruxtecan
AstraZeneca, Daiichi Sankyo
Non-small Cell Lung Cancer
03/28
05/32
MARIPOSA, NCT04487080 / 2020-000743-31: A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: From MARIPOSA trial in combination with amivantamab for advanced NSCLC
Active, not recruiting
3
1074
Europe, Canada, Japan, US, RoW
Amivantamab, JNJ-61186372, Osimertinib, Lazertinib, JNJ-73841937 and YH-25448, Placebo
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
04/24
06/27
ATTACK, NCT04870190: Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Not yet recruiting
3
232
NA
Almonertinib, HS-10296, Osimertinib, Teresa, AZD9291
Shanghai Chest Hospital
NSCLC
06/24
06/24
COMPEL, NCT04765059: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
98
Europe, US, RoW
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
AstraZeneca, Parexel
Non-small Cell Lung Cancer
12/24
12/24
NeoADAURA, NCT04351555 / 2020-000058-89: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Data from NeoADAURA trial for EGFRm NSCLC
Recruiting
3
328
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291; TAGRISSO, Cisplatin, Carboplatin, Placebo, Pemetrexed
AstraZeneca
Non-Small Cell Lung Cancer
07/24
06/29
TROPION Lung15, NCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruiting
3
630
NA
Dato-DXd, DS-1062a, Osimertinib, Tagrisso, AZD9291, Pemetrexed, Carboplatin, Cisplatin
AstraZeneca, Daiichi Sankyo
Metastatic Non-small Cell Lung Cancer
09/26
02/28
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Recruiting
3
250
RoW
Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
09/24
11/24
SANOVO, NCT05009836: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Recruiting
3
320
RoW
Savolitinib, HMPL-504, Placebo
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
11/24
01/25
ChiCTR2100045604: A randomized, open-label, multicenter, phase III study of osimertinib plus chemotherapy versus osimertinib monotherapy in EGFR active mutant NSCLC with concomitant mutation

Recruiting
3
296
 
osimertinib ;osimertinib plus chemotherapy
Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Tumor Hospital of Guangxi Medical University, Beijing Xisike Clinical Oncology Research Foundation
Lung cancer
 
 
ROSY-T, NCT05629234: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO)

Active, not recruiting
3
37
Europe, RoW
Osimertinib, TAGRISSO
AstraZeneca, Parexel
Cancer
02/25
02/25
FLETEO, NCT05382728: Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
680
RoW
TY-9591, TY-9591 Tablets, placebo Osimertinib, placebo Tagrisso, Osimertinib, Tagrisso, placebo TY-9591, placebo TY-9591 Tablets
TYK Medicines, Inc
NSCLC, EGFR Activating Mutation
05/25
12/27
SAFFRON, NCT05261399: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting
3
324
Europe, Canada, Japan, US, RoW
Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
06/25
12/26
PACIFIC-4, NCT03833154 / 2018-002572-41: Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Calendar Jan 2024 - Dec 2024: Data from PACIFIC-4 trial for stage I/II NSCLC
Calendar Jan 2024 - Dec 2024: Acceptance of submission for NSCLC (based on PACIFIC-4 trial)
Recruiting
3
690
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Osimertinib (single-arm, open-label)
AstraZeneca
Carcinoma, Non-Small-Cell Lung
03/26
04/28
NCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting
3
300
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD-9291, AZD9291, Mereletinib
National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/26
12/26
ADAURA2, NCT05120349: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291; TAGRISSO, Placebo
AstraZeneca
Non-Small Cell Lung Cancer
08/27
11/32
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn
3
250
NA
Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed
AbbVie
Non-Small Cell Lung Cancer
04/28
04/28
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Recruiting
2/3
14
RoW
SI-B001, Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
08/24
08/24

Download Options